Viscosupplementation Market Trends, Analysis & Forecast (2025–2033)

Viscosupplementation Market Size and Forecast (2025–2033)

According to Renub Research global viscosupplementation market is poised for strong growth over the forecast period, driven by the rising prevalence of osteoarthritis, aging populations, and increasing preference for non-surgical joint pain management solutions. The market was valued at US$ 4.66 billion in 2024 and is expected to reach US$ 10.16 billion by 2033, expanding at a compound annual growth rate (CAGR) of 9.02% from 2025 to 2033.

Viscosupplementation involves the injection of hyaluronic acid into joints to restore lubrication, reduce pain, and improve mobility. As awareness of minimally invasive orthopedic treatments continues to rise, viscosupplementation is increasingly being adopted as an effective alternative to surgery, particularly for knee osteoarthritis.

Viscosupplementation Market Outlook

Viscosupplementation is an ambulatory therapeutic procedure primarily used to manage joint pain caused by osteoarthritis. The treatment involves injecting hyaluronic acid or similar lubricating agents into the synovial joint, most commonly the knee. Hyaluronic acid is a naturally occurring substance in synovial fluid that provides cushioning and lubrication to joints.

In patients with osteoarthritis, the quality and quantity of synovial fluid decline due to cartilage degeneration and inflammation. Viscosupplementation restores lubrication, reduces friction between joint surfaces, and alleviates pain while improving joint function. The procedure is typically recommended for patients who have not achieved sufficient relief through oral medications or physical therapy.

Viscosupplementation is considered minimally invasive and generally associated with fewer complications compared to surgical interventions. While knee osteoarthritis remains the primary indication, the treatment is increasingly being used for other joints such as the hip and shoulder, expanding its clinical application scope.

Request a free sample copy of the report:https://www.renub.com/request-sample-page.php?gturl=viscosupplementation-market-p.php

Growth Driver: Increasing Prevalence of Osteoarthritis

The rising global burden of osteoarthritis is the most significant driver of the viscosupplementation market. Osteoarthritis is a leading cause of chronic pain and disability, particularly among older adults. Weight-bearing joints such as the knee are most commonly affected, significantly impacting mobility and quality of life.

As life expectancy increases worldwide, the number of individuals susceptible to joint degeneration continues to grow. Viscosupplementation offers a non-surgical, effective pain management option for this expanding patient population. Its ability to delay or reduce the need for joint replacement surgery further enhances its appeal among patients and healthcare providers.

Growth Driver: Rising Preference for Minimally Invasive Treatments

Healthcare systems globally are shifting toward minimally invasive treatment options to reduce recovery time, hospitalization costs, and procedural risks. Viscosupplementation aligns well with this trend, as it requires only outpatient injections with minimal downtime.

Patients increasingly prefer viscosupplementation over surgery due to faster recovery, lower complication risk, and reduced healthcare expenses. The growing emphasis on outpatient care and same-day procedures has further accelerated demand for injectable therapies, strengthening market growth.

Growth Driver: Advancements in Hyaluronic Acid Formulations

Continuous innovation in hyaluronic acid formulations has significantly improved the efficacy and durability of viscosupplementation treatments. Newer products offer longer-lasting pain relief with fewer injections, improving patient compliance and satisfaction.

Advanced formulations tailored to different stages of osteoarthritis have expanded treatment options and increased physician confidence in viscosupplementation. These developments have positioned viscosupplementation as a competitive alternative to traditional pharmacological therapies and physical rehabilitation.

Challenges: High Cost of Treatment

High treatment costs remain a major challenge for the viscosupplementation market. In many regions, insurance coverage for viscosupplementation is partial or limited, making the therapy financially inaccessible for a significant portion of the population.

The need for repeated injections over time further increases the overall cost burden. As a result, adoption rates may be lower in regions with limited reimbursement frameworks or lower healthcare spending, potentially restricting market growth.

Challenges: Limited Awareness and Adoption

Despite its proven benefits, viscosupplementation remains underutilized due to limited awareness among patients and some healthcare providers. Many osteoarthritis patients are unfamiliar with this treatment option and are often directed toward oral medications or surgical solutions.

Concerns regarding cost, variable clinical outcomes, and the need for multiple injections may also discourage adoption. Insufficient educational initiatives targeting both physicians and patients continue to hinder wider market penetration.

Single-Injection Viscosupplementation Market Trends

The single-injection viscosupplementation segment is expected to experience substantial growth during the forecast period. Single-injection products offer greater convenience for patients and physicians, reducing clinic visits and improving treatment adherence.

The growing emphasis on outpatient care and same-day procedures supports the adoption of single-injection therapies. Additionally, manufacturers are increasingly focusing on developing high-efficacy single-dose formulations, leading to more product launches and broader acceptance.

Knee Osteoarthritis Viscosupplementation Market Dominance

Knee osteoarthritis represents the largest and most dominant segment in the viscosupplementation market. The high prevalence of knee osteoarthritis, particularly among elderly populations, drives strong demand for hyaluronic acid injections.

Age-related cartilage degeneration and reduced shock-absorbing capacity make the knee especially vulnerable. The strong association between aging and knee osteoarthritis ensures sustained demand for viscosupplementation in this segment throughout the forecast period.

Orthopedic Clinics and Ambulatory Surgical Centers Market

Orthopedic clinics and ambulatory surgical centers are experiencing steady growth as preferred treatment settings for viscosupplementation procedures. These facilities offer specialized orthopedic care, shorter wait times, and reduced hospitalization requirements.

Patients increasingly favor outpatient centers due to convenience and efficiency. Advancements in orthopedic technologies and a patient-centric healthcare approach further support the expansion of these facilities within the viscosupplementation market.

United States Viscosupplementation Market

The United States represents one of the largest and most mature markets for viscosupplementation. Rising osteoarthritis prevalence, particularly among aging populations, is a major growth driver. Increasing awareness of non-surgical treatment alternatives and advancements in hyaluronic acid formulations support market expansion.

In November 2022, Anika Therapeutics Inc. achieved the primary endpoint in a Phase III study for Cingal, a long-acting viscosupplementation product for knee osteoarthritis. The company is pursuing FDA approval, strengthening innovation and competition in the U.S. market.

France Viscosupplementation Market

The viscosupplementation market in France is growing steadily due to an aging population and increasing osteoarthritis incidence. High awareness of non-surgical orthopedic treatments and a well-developed healthcare system support market adoption.

France’s focus on improving healthcare outcomes and accessibility has encouraged the use of minimally invasive therapies. Continuous innovation in hyaluronic acid products further supports market growth in the country.

China Viscosupplementation Market

The viscosupplementation market in China is influenced by demographic shifts, rising osteoarthritis prevalence, and evolving healthcare practices. Increasing patient preference for non-surgical treatments and growing awareness of joint health are driving market growth.

Ongoing research and innovation in hyaluronic acid formulations continue to support adoption. As healthcare infrastructure improves and access to advanced treatments expands, viscosupplementation demand is expected to rise steadily.

Saudi Arabia Viscosupplementation Market

Saudi Arabia’s viscosupplementation market is expanding due to rising joint health awareness and a growing elderly population. Advanced healthcare infrastructure and high healthcare expenditure facilitate the adoption of non-invasive treatments.

The preference for surgery-avoidance strategies and government initiatives to improve healthcare quality further support market growth. Increasing use of hyaluronic acid injections for knee osteoarthritis is strengthening demand in the country.

Key Players in the Viscosupplementation Market

The global viscosupplementation market is moderately consolidated, with leading players focusing on product innovation, regulatory approvals, and geographic expansion. Key companies include Zimmer Biomet, Smith & Nephew PLC, F. Hoffmann-La Roche Ltd, Sanofi, Chugai Pharmaceutical Co., Lifecore Biomedical, and LG Life Sciences Ltd.

In December 2023, Bioventus Inc. entered a nationwide agreement with Aetna Medicare Advantage plans, improving patient access to active healing and joint care solutions.

Demographic Trends Supporting Market Growth

According to demographic projections, the global population aged 65 and older is expected to increase significantly by 2050. This aging trend directly correlates with a higher incidence of osteoarthritis, expanding the patient pool for viscosupplementation therapies and supporting long-term market growth.

Viscosupplementation Market Segmentation Overview

The market is segmented by product type, including single, three, and five-injection regimens. By application, it covers knee, hip, hand/wrist, ankle/foot, and other joints. End users include hospitals and orthopedic clinics or ambulatory surgical centers.

Geographically, the market spans North America, Europe, Asia Pacific, Latin America, the Middle East & Africa, and the rest of the world, covering 25 countries across major regions.

Company Analysis Framework

Each company in the market is analyzed based on overview, recent developments, and revenue performance, providing a comprehensive understanding of competitive positioning and strategic direction.